New Vital Pulpotomy Medications in Primary Molars

Clinical and Radiographic Evaluation of Hyaluronic Acid and Biodentine as Vital Pulpotomy Medications in Primary Molars: Randomized Controlled Clinical Trial

Evaluate clinically and radiographically the effect of biodentine and hyaluronic acid (HA) versus formocresol (FC) as pulpotomy medications in primary molars.

Split mouth randomized controlled clinical trial. This study will be conducted on 96 teeth from 48 children in age group 4-7 years and have bilateral lower primary molars indicated for vital pulpotomy procedure. for:

1. Clinical evaluation of biodentine, hyaluronic acid and formocresol groups according to presence of failure criteria at different follow up periods.
2. Radiographic evaluation of biodentine, hyaluronic acid and formocresol groups according to presence of failure criteria at different follow up periods.

Inclusion Criteria:

• -Clinical criteria

  1. Restorable mandibular primary molars with deep carious lesions.
  2. Absence of gingival swelling or sinus tract.
  3. Absence of spontaneous pain
  4. Absence of pain on percussion. B-Radiographic Criteria: Absence of
  1. Discontinuity of lamina dura
  2. Internal root resorption.
  3. External root resorption.
  4. inter-radicular or periapical bone destruction (radiolucency)

Exclusion Criteria:

1. Excessive bleeding during pulp amputation.
2. Non vital/necrotic teeth.
3. Any sort of medical history contraindicating the pulp treatment.
4. Teeth approximate exfoliation
5. Patient's guardians are not intending to be part of the study.
6. Retreatment of previously pulpotomy treated molar -